Dr. David Mark Dobrzynski Jr., MD

Dr. Dobrzynski practices at Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center.

Dr. Dobrzynski's NPI, 1851659155, was assigned on April 25, 2012. Dr. Dobrzynski graduated from Albany Medical College of Union University in 2012. Dr. Dobrzynski holds New York license 293111.

Dr. Dobrzynski's primary practice is Strong Memorial Hospital, at 601 Elmwood Ave, Rochester, NY 14642 in Monroe County. The practice phone is (585) 275-2121.

Dr. Dobrzynski's primary practice is Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center. The medical group on file is University of Rochester Medical Faculty Group (URMFG). Dmand AI also links Dr. Dobrzynski to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dobrzynski practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Dobrzynski's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Dr. Dobrzynski's licenses on file in 2 states: New York and Tennessee.

CMS data shows 96 Medicare services from Dr. Dobrzynski across 5 procedure codes in 2024, for 66 Medicare patients. Medicare paid $8,697 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 66 Medicare patients who saw Dr. Dobrzynski in 2024. The largest group is under 65, with 26 patients. 75% of them have high blood pressure, and 62% have high cholesterol. 56% are also on Medicaid. Their average risk score is 3.39, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dobrzynski's median patient age at 64, with 42% women.

In 2024, Dr. Dobrzynski wrote 108 Medicare Part D claims for 26 patients. 94% of them were for generic drugs. CMS names the drug for 55 of them, across 4 drugs with 11 or more claims each, at $1,524 in total drug cost. In 2023, CMS named 75 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Dobrzynski for performance year 2024, reported as part of a group. Dr. Dobrzynski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dobrzynski as offering telehealth.

Dmand AI links 10 papers to Dr. Dobrzynski, published from 2021 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Anti-Bacterial Agents and Bacteremia. Dr. Dobrzynski has published most often in J Infect Dis. Dr. Dobrzynski's most frequent co-authors are Robert L. Atmar, MD, John H. Beigel, MD and Rebecca C. Brady, MD.

CMS Open Payments shows 2 general payments to Dr. Dobrzynski from 1 drug or device company in 2023. Consulting fees make up the largest share, 100% of the total. La Jolla Pharmaceutical Company paid the most, $1,887.

Dr. Dobrzynski graduated from Albany Medical College of Union University in 2012.